Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Viking Therapeutics, Inc. (VKTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/27/2022 8-K Quarterly results
Docs: "Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update"
04/27/2022 8-K Quarterly results
Docs: "Viking Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update"
02/09/2022 8-K Quarterly results
11/03/2021 8-K Quarterly results
Docs: "Viking Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update"
02/17/2021 8-K Quarterly results
10/28/2020 8-K Quarterly results
Docs: "Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH Ongoing • Phase 1 Trial Evaluating VK0214 for the Treatment of X-ALD Underway • Balance Sheet Remains Strong; Quarter-End Cash Approximately $255 Million SAN DIEGO, October 28, 2020 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2020, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended Septembe..."
07/29/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH • New Data from VK2809 Phase 2 NAFLD Trial to be Highlighted at EASL • IND Filing for VK0214 in X-ALD on Track for Mid-Year • Balance Sheet Remains Strong, Quarter-End Cash Approximately $270 Million SAN DIEGO, April 30, 2020 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2020, and provided an update on its clinical pipeline and other corporate developments. Highlights fr..."
11/05/2019 8-K Quarterly results
Docs: "Viking Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 8:30 a.m. ET today • IND Application Filed for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH • Clinical Development of VK0214 for X-ALD Expected to Begin 1H20 • Balance Sheet Remains Strong with Approximately $290 Million in Cash SAN DIEGO, November 5, 2019 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter ended September 30, 2019, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter, and Subsequent to September 30, 2019..."
08/01/2019 8-K Quarterly results
Docs: "Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Preparation for Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Underway; Expect to Commence Enrollment in 2H19 • Continued Progress with VK0214 for X-ALD; Expect to Commence Phase 1 Clinical Study in 1H20 SAN DIEGO, August 1, 2019 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter ended June 30, 2019, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter, and Subsequent to June 30, 2019: “The second quarter ..."
05/02/2019 8-K Quarterly results
Docs: "Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • New Data from Phase 2 Study of VK2809 Presented at EASL 2019; Results Demonstrate Robust Efficacy at Doses as Low as 5 mg Daily • Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Expected to Commence in 2H19 • IND Filing for VK0214 in X-ALD Planned in 2H19 SAN DIEGO, May 2, 2019 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2019, and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter, ..."
03/13/2019 8-K Quarterly results
Docs: "Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • Additional VK2809 Phase 2 Data to be Presented at EASL 2019; Results Demonstrate Promising Efficacy at Doses as Low as 5 mg Daily • Initiation of Phase 2b Study of VK2809 in Biopsy-Confirmed NASH Planned for 2H19 • Year-End Cash of Approximately $302 Million Provides Runway Through at Least 2021 SAN DIEGO, March 13, 2019 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2018, and provided an update on its clinical pip..."
03/07/2018 8-K Quarterly results
Docs: "Viking Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update Conference call scheduled for 4:30 p.m. ET today • VK5211 Phase 2 trial in hip fracture achieves primary and multiple secondary endpoints • VK2809 Phase 2 fatty liver and hypercholesterolemia study proceeding, results expected 2H18 • Orphan disease programs targeting GSD Ia and X-ALD progressing into clinical development • Strengthened balance sheet; raised approximately $78 million in gross proceeds through recent offerings of common stock SAN DIEGO, March 7, 2018 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial resu..."
11/08/2017 8-K Quarterly results
Docs: "Viking Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update • VK5211 Phase 2 hip fracture study nearing completion, data expected 4Q17 • VK2809 Phase 2 fatty liver and hypercholesterolemia study proceeding • Final VK2809 data from in vivo NASH model demonstrates significant improvements in fibrosis, steatosis and NAFLD activity score • Positive data presentations support continued development of orphan drug programs in GSD Ia and X-ALD • Conference call scheduled for 4:30 pm ET today SAN DIEGO, November 8, 2017 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third qu..."
08/09/2017 8-K Quarterly results
Docs: "Viking Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update • VK5211 Phase 2 hip fracture study fully enrolled, data expected 4Q17 • VK2809 Phase 2 fatty liver and hypercholesterolemia study proceeding • In vivo data for VK2809 in NASH demonstrate histologic benefits on steatosis, fibrosis, NAFLD Activity Score • Viking board of directors and balance sheet strengthened SAN DIEGO, August 9, 2017 -- Viking Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter ended June 30, 2017, and provided an update on its clinical pipeline and other corporate developments. Highlights from..."
05/10/2017 8-K Form 8-K - Current report
03/21/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
08/10/2016 8-K Quarterly results
Docs: "Viking Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update"
05/10/2016 8-K Quarterly results
Docs: "Viking Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update - VK5211 Phase 2 study for hip fracture ongoing - Positive Phase 1b data on VK2809 presented at American College of Cardiology -"
03/08/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Viking Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update"
08/13/2015 8-K Quarterly results
Docs: "Viking Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy